ArticleDrug design, development and therapy2026
Modified Jie-Yu-He-Huan Capsule in Post-Stroke Depression Treatment: Insights from DIA Proteomic and PRM Validation.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Post-stroke depression (PSD), a prevalent neuropsychiatric complication of stroke, manifests as persistent low mood and depressive symptoms secondary to cerebrovascular injury, contributing to increased morbidity and mortality. Although the modified Jie-Yu-He-Huan (MJYHH) capsule has demonstrated clinical efficacy in alleviating PSD symptoms, its pharmacological targets and mechanisms of action remain unclear. Methods: Pharmacological screening was performed on healthy C57BL/6 mice, revealing significant antidepressant effects of MJYHH. A PSD rat model was subsequently established through combined middle cerebral artery occlusion (MCAO), social isolation, and chronic mild stress (CMS). Behavioural tests were conducted to evaluate therapeutic outcomes. Data-independent acquisition (DIA) and parallel reaction monitoring (PRM) technologies were employed to investigate the traditional Chinese medicine (TCM) mechanisms. Results: The PSD model group exhibited characteristic depressive behaviours, which were significantly attenuated by MJYHH treatment. Proteomic analysis identified 16 differentially expressed proteins (DEPs), with subsequent Gene Ontology (GO), KEGG pathway, and protein-protein interaction (PPI) network analyses demonstrating their predominant association with: biosynthetic and metabolic pathways, oxidative stress response, mitochondrial dysfunction.PRM validation and molecular docking studies further implicated three key targets (Rrm2b, Cyp51a1, and Rhot2) as potential mediators of MJYHH's therapeutic effects. Conclusion: This integrated investigation combining animal models, omics technologies, and computational approaches elucidates the multi-target mechanism of MJYHH capsule in PSD treatment, providing a scientific foundation for TCM-based intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.